{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:38Z","timestamp":1791874718310,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.canlet.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T17:26:48Z","timestamp":1633973208000},"page":"232-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells"],"prefix":"10.1016","volume":"524","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1570-4708","authenticated-orcid":false,"given":"Laura","family":"Streit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-0480","authenticated-orcid":false,"given":"Sophie","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-3601","authenticated-orcid":false,"given":"Sylvain","family":"Hugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Rame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Tanguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Andry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert A.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5182-6660","authenticated-orcid":false,"given":"Laurent","family":"Brunaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Bihain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Nomin\u00e9-Criqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-3437","authenticated-orcid":false,"given":"Yannick","family":"Goumon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lacomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lomazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9303-2364","authenticated-orcid":false,"given":"Michel","family":"Vix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-4907","authenticated-orcid":false,"given":"Nicolas","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-1157","authenticated-orcid":false,"given":"St\u00e9phane","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7114-2100","authenticated-orcid":false,"given":"St\u00e9phane","family":"Gasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.10.009_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071859","article-title":"Hormones secretion and Rho GTPases in neuroendocrine tumors","volume":"12","author":"Streit","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.10.009_bib2","doi-asserted-by":"crossref","first-page":"8341426","DOI":"10.1155\/2020\/8341426","article-title":"Update on pathophysiology, treatment, and complications of carcinoid syndrome","volume":"2020","author":"Clement","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.canlet.2021.10.009_bib3","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/ERC-16-0538","article-title":"Effect of hormone secretory syndromes on neuroendocrine tumor prognosis","volume":"24","author":"Zandee","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2021.10.009_bib4","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but net: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2021.10.009_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canlet.2021.10.009_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2021.10.009_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.canlet.2021.10.009_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11906-018-0804-z","article-title":"Pheochromocytomas and hypertension","volume":"20","author":"Pappachan","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.canlet.2021.10.009_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms","volume":"15","author":"Pourian","year":"2015","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.canlet.2021.10.009_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082435","article-title":"Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas","volume":"9","author":"Y-Hassan","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2021.10.009_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2017.07.014","article-title":"Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature","volume":"249","author":"Zhang","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.canlet.2021.10.009_bib12","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1210\/jc.2012-3669","article-title":"Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?","volume":"98","author":"Stolk","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2021.10.009_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1445-5994.2000.tb04358.x","article-title":"Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland","volume":"30","author":"McNeil","year":"2000","journal-title":"Aust. N. Z. J. Med."},{"key":"10.1016\/j.canlet.2021.10.009_bib14","first-page":"299","article-title":"Death from phaeochromocytoma: lessons from a post-mortem survey","volume":"29","author":"Platts","year":"1995","journal-title":"J. R. Coll Physicians Lond."},{"key":"10.1016\/j.canlet.2021.10.009_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-018-4181-2","article-title":"Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management","volume":"35","author":"Jain","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.canlet.2021.10.009_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2044.2005.04156.x","article-title":"The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas","volume":"60","author":"Lebuffe","year":"2005","journal-title":"Anaesthesia"},{"key":"10.1016\/j.canlet.2021.10.009_bib17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.surg.2014.08.022","article-title":"Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma","volume":"156","author":"Brunaud","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2021.10.009_bib18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/14656566.2017.1391217","article-title":"Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects","volume":"18","author":"Mazziotti","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.canlet.2021.10.009_bib19","doi-asserted-by":"crossref","first-page":"R551","DOI":"10.1530\/ERC-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future","volume":"23","author":"Oberg","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2021.10.009_bib20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1530\/ERC-14-0086","article-title":"Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures","volume":"21","author":"Mohamed","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2021.10.009_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1634\/theoncologist.2016-0305","article-title":"The antiproliferative role of lanreotide in controlling growth of neuroendocrine tumors: a systematic review","volume":"22","author":"Michael","year":"2017","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2021.10.009_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.10.009_bib24","first-page":"227","article-title":"Pasireotide: a novel treatment for patients with acromegaly","volume":"10","author":"Cuevas-Ramos","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.canlet.2021.10.009_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical treatment of cushing's disease: an overview of the current and recent clinical trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2021.10.009_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2021.10.009_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/JME-08-0012","article-title":"Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells","volume":"40","author":"Pasquali","year":"2008","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib29","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2021.10.009_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"Toledo","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1373\/clinchem.2004.045484","article-title":"Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines","volume":"51","author":"Eisenhofer","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.canlet.2021.10.009_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2021.10.009_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-0716-1044-2_11","article-title":"Bovine chromaffin cells: culture and fluorescence assay for secretion","volume":"2233","author":"Thahouly","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2021.10.009_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000491578","article-title":"18F-FDOPA PET\/CT uptake parameters correlate with catecholamine secretion in human pheochromocytomas","volume":"107","author":"Moog","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.canlet.2021.10.009_bib35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1520\/JFS13868J","article-title":"Selecting an appropriate isotopic internal standard for gas chromatography\/mass spectrometry analysis of drugs of abuse--pentobarbital example","volume":"40","author":"Liu","year":"1995","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.canlet.2021.10.009_bib36","doi-asserted-by":"crossref","first-page":"108026","DOI":"10.1016\/j.celrep.2020.108026","article-title":"Mono- and poly-unsaturated phosphatidic acid regulate distinct steps of regulated exocytosis in neuroendocrine cells","volume":"32","author":"Tanguy","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.10.009_bib37","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1523\/JNEUROSCI.4048-14.2015","article-title":"Oligophrenin-1 connects exocytotic fusion to compensatory endocytosis in neuroendocrine cells","volume":"35","author":"Houy","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.canlet.2021.10.009_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0165-0270(00)00309-5","article-title":"Automatic analysis for amperometrical recordings of exocytosis","volume":"103","author":"Segura","year":"2000","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.canlet.2021.10.009_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0006-8993(79)90714-5","article-title":"Pharmacological characterization of adrenal paraneurons: substance P and somatostatin as inhibitory modulators of the nicotinic response","volume":"178","author":"Mizobe","year":"1979","journal-title":"Brain Res."},{"key":"10.1016\/j.canlet.2021.10.009_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0006-8993(89)90362-4","article-title":"Actions of somatostatin on perfused bovine adrenal glands and cultured bovine adrenal medullary cells","volume":"484","author":"Moeller","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.canlet.2021.10.009_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nmeth782","article-title":"Analysis of exocytotic events recorded by amperometry","volume":"2","author":"Mosharov","year":"2005","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2021.10.009_bib42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-1044-2_15","article-title":"Amperometry in single cells and tissue","volume":"2233","author":"Keating","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2021.10.009_bib43","doi-asserted-by":"crossref","first-page":"C572","DOI":"10.1152\/ajpcell.1995.269.3.C572","article-title":"Role of [Na+]i and [Ca2+]i in nicotine-induced norepinephrine release from bovine adrenal chromaffin cells","volume":"269","author":"Gerber","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.canlet.2021.10.009_bib44","first-page":"175","article-title":"Non-functioning neuroendocrine pancreatic tumors transforming to malignant insulinomas - four cases and review of the literature","volume":"40","author":"Juhlin","year":"2019","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.canlet.2021.10.009_bib45","first-page":"214","article-title":"Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma","volume":"63","author":"Song","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.10.009_bib46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1530\/eje.1.02141","article-title":"A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry","volume":"154","author":"Brown","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-008-0085-7","article-title":"Modification of hormonal secretion in clinically silent pituitary adenomas","volume":"12","author":"Daems","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.canlet.2021.10.009_bib48","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2021.10.009_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.10.009_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.regpep.2006.06.002","article-title":"The release of 3H-1-methyl-4-phenylpyridinium from bovine adrenal chromaffin cells is modulated by somatostatin","volume":"137","author":"Ribeiro","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.canlet.2021.10.009_bib51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000183786","article-title":"Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors","volume":"40","author":"Invitti","year":"1993","journal-title":"Horm. Res."},{"key":"10.1016\/j.canlet.2021.10.009_bib52","first-page":"46","article-title":"Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies","volume":"53","author":"Koriyama","year":"2000","journal-title":"Horm. Res."},{"key":"10.1016\/j.canlet.2021.10.009_bib53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2265.1995.tb01877.x","article-title":"Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial","volume":"42","author":"Plouin","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2265.2002.01658.x","article-title":"Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma","volume":"57","author":"Lamarre-Cliche","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib55","doi-asserted-by":"crossref","first-page":"E391","DOI":"10.1002\/hed.23348","article-title":"Effects of octreotide therapy in progressive head and neck paragangliomas: case series","volume":"35","author":"van Hulsteijn","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.canlet.2021.10.009_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib57","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2021.10.009_bib58","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.surg.2012.08.021","article-title":"Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model","volume":"152","author":"Quinn","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2021.10.009_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ibanez-Costa","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib60","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1210\/jc.2008-1712","article-title":"Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies","volume":"94","author":"van Hoek","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2021.10.009_bib61","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2006.07.006","article-title":"Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues","volume":"138","author":"Ludvigsen","year":"2007","journal-title":"Regul. Pept."},{"key":"10.1016\/j.canlet.2021.10.009_bib63","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1523\/JNEUROSCI.0860-08.2008","article-title":"A fast mode of membrane fusion dependent on tight SNARE zippering","volume":"28","author":"Bretou","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.canlet.2021.10.009_bib64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0896-6273(01)00418-4","article-title":"Quantal size is dependent on stimulation frequency and calcium entry in calf chromaffin cells","volume":"31","author":"Elhamdani","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.canlet.2021.10.009_bib65","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/0306-4522(81)90215-3","article-title":"Somatostatin and substance P inhibit catecholamine secretion from isolated cells of Guinea-pig adrenal medulla","volume":"6","author":"Role","year":"1981","journal-title":"Neuroscience"},{"key":"10.1016\/j.canlet.2021.10.009_bib66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1139\/y84-076","article-title":"Receptors and receptor modulation in cultured chromaffin cells","volume":"62","author":"Livett","year":"1984","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.canlet.2021.10.009_bib67","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/0006-291X(91)91481-Q","article-title":"Somatostatin inhibits the nicotinic receptor-activated inward current in Guinea pig chromaffin cells","volume":"174","author":"Inoue","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2021.10.009_bib68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.10.009_bib69","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1210\/me.2007-0334","article-title":"Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization","volume":"22","author":"Grant","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2021.10.009_bib70","doi-asserted-by":"crossref","first-page":"14027","DOI":"10.1074\/jbc.M006084200","article-title":"Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A)","volume":"276","author":"Pfeiffer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.009_bib71","doi-asserted-by":"crossref","first-page":"19762","DOI":"10.1074\/jbc.M110373200","article-title":"Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization","volume":"277","author":"Pfeiffer","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.009_bib72","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cellsig.2011.01.002","article-title":"Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta1-adrenergic receptor and somatostatin receptor-5","volume":"23","author":"Somvanshi","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2021.10.009_bib73","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"European network for the study of adrenal, prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100519X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100519X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:02:16Z","timestamp":1759593736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352100519X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":73,"alternative-id":["S030438352100519X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}